Brokerages predict that NeoGenomics, Inc. (NASDAQ:NEO) will report earnings of $0.04 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for NeoGenomics’ earnings. The highest EPS estimate is $0.05 and the lowest is $0.04. NeoGenomics also reported earnings of $0.04 per share during the same quarter last year. The business is scheduled to issue its next earnings report before the market opens on Tuesday, July 24th.
According to Zacks, analysts expect that NeoGenomics will report full-year earnings of $0.18 per share for the current fiscal year, with EPS estimates ranging from $0.16 to $0.19. For the next year, analysts expect that the firm will post earnings of $0.26 per share, with EPS estimates ranging from $0.24 to $0.30. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow NeoGenomics.
NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, May 1st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.01. NeoGenomics had a negative net margin of 0.86% and a positive return on equity of 3.19%. The business had revenue of $63.40 million for the quarter, compared to analyst estimates of $62.31 million. During the same quarter last year, the business earned $0.03 earnings per share. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year.
NeoGenomics traded up $0.07, reaching $14.12, on Friday, according to Marketbeat Ratings. 473,998 shares of the company’s stock were exchanged, compared to its average volume of 451,635. The firm has a market capitalization of $1.13 billion, a PE ratio of 235.33, a PEG ratio of 6.69 and a beta of 0.52. NeoGenomics has a twelve month low of $7.08 and a twelve month high of $14.61. The company has a current ratio of 2.03, a quick ratio of 1.85 and a debt-to-equity ratio of 0.53.
In other NeoGenomics news, insider Robert J. Shovlin sold 12,941 shares of NeoGenomics stock in a transaction dated Friday, June 29th. The shares were sold at an average price of $13.12, for a total transaction of $169,785.92. Following the transaction, the insider now directly owns 39,884 shares of the company’s stock, valued at $523,278.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jennifer Balliet sold 13,000 shares of NeoGenomics stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $11.24, for a total transaction of $146,120.00. Following the transaction, the vice president now directly owns 13,000 shares in the company, valued at $146,120. The disclosure for this sale can be found here. Insiders have sold 708,707 shares of company stock worth $8,692,086 over the last 90 days. 12.20% of the stock is currently owned by company insiders.
Hedge funds have recently modified their holdings of the business. Cornerstone Wealth Management LLC purchased a new stake in shares of NeoGenomics in the 2nd quarter valued at approximately $528,000. WINTON GROUP Ltd purchased a new stake in shares of NeoGenomics in the 1st quarter valued at approximately $338,000. Segall Bryant & Hamill LLC raised its stake in shares of NeoGenomics by 1.6% in the 1st quarter. Segall Bryant & Hamill LLC now owns 441,380 shares of the medical research company’s stock valued at $3,602,000 after acquiring an additional 6,952 shares during the period. First Light Asset Management LLC raised its stake in shares of NeoGenomics by 23.7% in the 1st quarter. First Light Asset Management LLC now owns 4,760,332 shares of the medical research company’s stock valued at $38,844,000 after acquiring an additional 912,730 shares during the period. Finally, Barclays PLC raised its stake in shares of NeoGenomics by 385.3% in the 1st quarter. Barclays PLC now owns 53,295 shares of the medical research company’s stock valued at $435,000 after acquiring an additional 42,314 shares during the period. 83.26% of the stock is currently owned by institutional investors.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.
Further Reading: Are Wall Street analysts’ stock ratings worth following?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.